Venaxis Presentation Rescheduled for 2013 BIO CEO and Investor Conference
CASTLE ROCK, Colo., Feb. 11, 2013
President & CEO Steve Lundy to Present on February 12, 2013 at 10:00 am ET
CASTLE ROCK, Colo., Feb. 11, 2013 /PRNewswire/ --Venaxis, Inc. (Nasdaq:
APPY), an in vitro diagnostic company focused on obtaining FDA clearance and
commercializing its blood-based appendicitis test, APPY1, today announced that
its presentation at the 2013 BIO CEO and Investor Conference, to be held
February 11-12, 2013, at the Waldorf Astoria Hotel in New York, has been
rescheduled for Tuesday, February 12, 2013.
Steve Lundy, President and CEO of Venaxis, will provide an overview of the
Company's business during his live presentation and will be available to
participate in one-on-one meetings with investors who are registered to attend
Event: BIO CEO and Investor Conference
Date: Tuesday, February 12, 2013
Time: 10:00 am (Eastern Time)
Location: Astor Room, 3^rd Floor; Waldorf Astoria Hotel; New York
The presentation will be webcast live. To access the webcast, please visit
the investor relations section of the Venaxis website at
http://ir.venaxis.com. The webcast replay will remain available for 90 days.
About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical
development and commercialization of its blood-based appendicitis test,
APPY1. The unique appendicitis test has projected high sensitivity and
negative predictive value and is designed to aid in the identification of
patients at low risk for acute appendicitis, allowing for more conservative
patient management. APPY1 is being developed initially for pediatric,
adolescent and young adult patients with abdominal pain, as this population is
at the highest risk for appendicitis and has the highest risk of long-term
health effects associated with CT imaging. For more information, visit
This press release includes "forward-looking statements" of Venaxis, Inc.
("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and
Exchange Commission ("SEC"). All statements, other than statements of
historical fact, included in this press release that address activities,
events or developments that Venaxis believes or anticipates will or may occur
in the future are forward-looking statements. These statements are based on
certain assumptions made based on experience, expected future developments and
other factors Venaxis believes are appropriate in the circumstances. Such
statements are subject to a number of assumptions, risks and uncertainties,
many of which are beyond the control of Venaxis. Investors are cautioned that
any such statements are not guarantees of future performance. Actual results
or developments may differ materially from those projected in the
forward-looking statements as a result of many factors, including our ability
to successfully complete required product development and modifications in a
timely and cost effective manner, complete clinical trial activities for APPY1
required for FDA submission, obtain FDA clearance or approval, maintain CE
Marking, cost effectively manufacture and generate revenues from APPY1,
execute agreements required to successfully advance the company's objectives,
retain the management team to advance the products, overcome adverse changes
in market conditions and the regulatory environment, obtain and enforce
intellectual property rights, and realize value of intangible assets.
Furthermore, Venaxis does not intend (and is not obligated) to update publicly
any forward-looking statements. The contents of this press release should be
considered in conjunction with the risk factors contained in Venaxis' recent
filings with the SEC, including its Form 10-Q for the period ended September
30, 2012, filed on November 7, 2012.
For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
SOURCE Venaxis, Inc.
Press spacebar to pause and continue. Press esc to stop.